146 related articles for article (PubMed ID: 34096893)
1. Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; González Font AE; Córdova Hurtado LP; Castañeda VL; Fierro IV; Romero LP; Reyes HA
Pharmacogenet Genomics; 2021 Jul; 31(5):108-115. PubMed ID: 34096893
[TBL] [Abstract][Full Text] [Related]
2. Genotype Analysis of
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; Chairez Hernández I; Córdova Hurtado LP; Loera Castañeda V; Patrón Romero L; Venzor Sánchez C; Payan Gándara H; Arechiga Gurrola D; Almanza Reyes H
Front Pharmacol; 2020; 11():616630. PubMed ID: 33613283
[No Abstract] [Full Text] [Related]
3. Impact of single-nucleotide variants and nutritional status on population pharmacokinetics of Doxorubicin, and its effect on cardiotoxicity in children with leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Fierro IV; Castañeda VL; Cordova Hurtado LP; González CD; Romero LP; Reyes HA
J Oncol Pharm Pract; 2023 Sep; 29(6):1290-1305. PubMed ID: 36113156
[TBL] [Abstract][Full Text] [Related]
4. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Hertz DL; Caram MV; Kidwell KM; Thibert JN; Gersch C; Seewald NJ; Smerage J; Rubenfire M; Henry NL; Cooney KA; Leja M; Griggs JJ; Rae JM
Pharmacogenomics; 2016 Feb; 17(3):231-40. PubMed ID: 26799497
[TBL] [Abstract][Full Text] [Related]
5. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
[TBL] [Abstract][Full Text] [Related]
6. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia.
Semsei AF; Erdelyi DJ; Ungvari I; Csagoly E; Hegyi MZ; Kiszel PS; Lautner-Csorba O; Szabolcs J; Masat P; Fekete G; Falus A; Szalai C; Kovacs GT
Cell Biol Int; 2012 Jan; 36(1):79-86. PubMed ID: 21929509
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
[TBL] [Abstract][Full Text] [Related]
8. Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia.
Hagag AA; Badraia IM; El-Shehaby WA; Mabrouk MM
J Oncol Pharm Pract; 2020 Sep; 26(6):1397-1406. PubMed ID: 31964219
[TBL] [Abstract][Full Text] [Related]
9. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for anthracycline-associated cardiotoxicity.
Reinbolt RE; Patel R; Pan X; Timmers CD; Pilarski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2016 May; 24(5):2173-2180. PubMed ID: 26563179
[TBL] [Abstract][Full Text] [Related]
13. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
[TBL] [Abstract][Full Text] [Related]
14. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.
Cascales A; Pastor-Quirante F; Sánchez-Vega B; Luengo-Gil G; Corral J; Ortuño-Pacheco G; Vicente V; de la Peña FA
Oncologist; 2013; 18(4):446-53. PubMed ID: 23576480
[TBL] [Abstract][Full Text] [Related]
15. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity.
Wojnowski L; Kulle B; Schirmer M; Schlüter G; Schmidt A; Rosenberger A; Vonhof S; Bickeböller H; Toliat MR; Suk EK; Tzvetkov M; Kruger A; Seifert S; Kloess M; Hahn H; Loeffler M; Nürnberg P; Pfreundschuh M; Trümper L; Brockmöller J; Hasenfuss G
Circulation; 2005 Dec; 112(24):3754-62. PubMed ID: 16330681
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Polymorphisms in ATP-Binding Cassette Transporter Genes on Anthracycline-Induced Early Cardiotoxicity in Patients with Breast Cancer.
Muckiene G; Vaitiekus D; Zaliaduonyte D; Bartnykaite A; Plisiene J; Zabiela V; Juozaityte E; Jurkevicius R
J Cardiovasc Dev Dis; 2023 May; 10(6):. PubMed ID: 37367397
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.
Samosir SM; Utamayasa IKA; Andarsini MR; Rahman MA; Ontoseno T; Hidayat T; Ugrasena IDG; Larasati MCS; Cahyadi A
Asian Pac J Cancer Prev; 2021 May; 22(5):1407-1412. PubMed ID: 34048168
[TBL] [Abstract][Full Text] [Related]
18. CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.
Lang JK; Karthikeyan B; Quiñones-Lombraña A; Blair RH; Early AP; Levine EG; Sharma UC; Blanco JG; O'Connor T
Cardiooncology; 2021 May; 7(1):17. PubMed ID: 33975650
[TBL] [Abstract][Full Text] [Related]
19. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
